Lttl review

Lttl publishes a full price matrix before checkout. Sermorelin and the three NAD⁺ forms start at $149 for a four-week supply; longer supplies require 12-, 24- or 52-week prepayment. Its terms name four pharmacy partners and claim service across all 50 states plus DC, subject to product availability. The terms promise a full refund if a clinician finds you ineligible at intake, but other pages say a consultation fee may remain after review; medication refund cutoffs also conflict. Get the applicable charges and refund terms in writing.

Lttl (pronounced "little") is a direct-to-consumer telehealth brand owned and operated by The Commerce Group Holdings, LLC. Its weight-loss line covers compounded semaglutide and tirzepatide as injectables, an oral dissolving-tablet semaglutide, and a microdose line for both molecules. Its longevity line covers sermorelin, glutathione, methylene blue, MIC B12, L-carnitine, and NAD⁺ in three forms — injectable, nasal spray and oral liposomal liquid. A separate peptide program is announced as coming soon, with no prices yet. Clinical services are delivered by independent networks of US-licensed clinicians, and it bills one flat rate regardless of dose.

Lttl begins with an asynchronous assessment reviewed by a licensed clinician, then ships prescribed medication through a pharmacy partner. Its terms name RedRock Compounding Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx; they do not identify which will dispense a given order. The terms claim services across all 50 states and Washington DC while warning that particular services may be unavailable in some places. The published inclusions describe access to a care team and cold-chain shipping where needed, but an insurance page allows applicable consultation fees after review, so the exact final charge needs confirmation. The site states flat dose pricing. A banner promises prescription and shipping within 48 hours, while its shipping policy allows two to five business days to process plus three to seven to deliver. The footer displays a self-hosted LegitScript badge linked to a general lookup page.

The matrix prices 4-, 12-, 24- and 52-week supplies, not equal calendar-month blocks. Sermorelin and the injectable, nasal and oral NAD⁺ forms are $149 for four weeks; 12 weeks cost $417 ($139 per four weeks) and 24 weeks cost $774 ($129 per four weeks). The 52-week supply costs $1,188 up front and is advertised as $99 monthly, not $99 per four weeks. Glutathione, MIC B12, L-carnitine and methylene blue start at $119 for four weeks, with lower prepaid equivalents. The separate $99 sermorelin/NAD⁺ and $89 other-product introductory offers apply to the first four-week supply only. Flat dose pricing is advertised. The terms promise a full refund when an initial clinician review finds a patient ineligible, while the returns and insurance pages say consultation fees may be nonrefundable after review. The terms make medication nonrefundable after intake submission, but the returns page names pharmacy shipment as the cutoff. Confirm the applicable fee, renewal cadence and refund trigger before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Lttl's own FAQ is unusually blunt — its compounded products are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality — and its terms name RedRock, Health Warehouse, Precision and Triad Rx as possible partners without assigning a specific dispenser, so compounded sterile products carry the usual caveat that the FDA does not review them for purity and potency. On evidence the longevity ladder is a mix. Sermorelin is a GHRH analog that stimulates your own pituitary; the mechanism is real and well described, and the long-term human outcome data is thin. NAD⁺ deserves particular care here because Lttl sells three routes: injected, intranasal and oral liposomal NAD⁺ all lack controlled human outcome trials, and the intranasal and liposomal routes have the weakest pharmacokinetic support of the three — the NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials show is a raised blood NAD⁺ level rather than a clinical benefit. Injectable glutathione has essentially no controlled human outcome data. Methylene blue is a genuinely approved drug for methemoglobinemia being sold here for cognitive and mitochondrial claims that have no controlled human outcome trials behind them, and it interacts seriously with serotonergic medications including SSRIs — a question to raise explicitly at intake. Individual results vary.